Modafinil

證據等級: L5

預測適應症: 1 個

Modafinil: From Narcolepsy / Excessive Daytime Sleepiness to Insomnia

One-Sentence Summary

Modafinil is a wakefulness-promoting agent approved globally for narcolepsy, obstructive sleep apnea-associated excessive sleepiness, and shift work sleep disorder — but currently carries no marketing authorization in Italy. The TxGNN model predicts it may have relevance for Insomnia, with 29 clinical trials and 19 publications identified in the evidence search. However, the vast majority address daytime sleepiness rather than insomnia directly, and a fundamental mechanistic paradox significantly undermines the plausibility of this prediction.

Quick Overview

Item	Content
Original Indication	Narcolepsy, OSA-associated excessive sleepiness, shift work sleep disorder (globally approved; no Italy marketing authorization)
Predicted New Indication	Insomnia (disease)
TxGNN Prediction Score	99.85%
Evidence Level	L4
Italy Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this Evidence Pack. Based on published literature, modafinil is a wakefulness-promoting agent that inhibits the dopamine transporter (DAT), thereby increasing synaptic dopamine availability in wake-promoting circuits. It also enhances norepinephrine (NE) and orexin/hypocretin signaling — effects that collectively sustain alertness and counteract pathological sleepiness. These properties underpin its approved uses across narcolepsy, obstructive sleep apnea (residual excessive sleepiness), and shift work sleep disorder.

Because modafinil carries approved indications across multiple sleep disorder subtypes, all of which cluster together in the TxGNN knowledge graph, the model likely generated a high prediction score (99.85%) based on topological proximity to insomnia rather than a directional therapeutic signal. One Phase 4 trial (NCT00124384) did specifically enroll primary insomnia patients, though the study aim was to improve daytime functioning when modafinil was added to cognitive behavioral therapy — not to treat nighttime sleep difficulties directly.

Critical mechanistic concern: There is a fundamental paradox at the core of this prediction. Insomnia is characterised by unwanted wakefulness and difficulty maintaining sleep, and effective treatment requires agents that facilitate sleep onset or maintenance. Modafinil, however, promotes wakefulness — and is itself classified as a drug that can cause insomnia as an adverse effect. This prediction almost certainly reflects a knowledge-graph false positive: graph proximity to sleep disorder nodes does not capture the directionality of pharmacological action. This prediction should be interpreted with extreme caution and does not constitute a credible repurposing candidate without additional mechanistic justification.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00124384	Phase 4	Completed	40	Modafinil alone or combined with CBT-I in primary insomnia; primary goal was improving daytime functioning, with secondary assessment of insomnia severity — does not constitute an insomnia treatment trial
NCT01091974	Phase 2	Completed	138	CBT-I ± armodafinil for insomnia and fatigue in breast cancer survivors post-chemotherapy; four-arm design; armodafinil intended to counter cancer-related fatigue, not as a direct sleep aid
NCT01019187	Phase 2	Completed	226	CBT-I ± armodafinil in cancer survivors with insomnia and fatigue after chemotherapy; same rationale as NCT01091974 — larger companion study
NCT01011218	Phase 2	Completed	70	Pilot study of BBT-I ± armodafinil 150 mg/day in breast cancer patients with insomnia; preliminary design, limited power
NCT02552303	N/A	Completed	39	Armodafinil and/or CBT-I for insomnia comorbid with obstructive sleep apnea; assessed sleep continuity and CPAP adherence — small sample, no Phase designation
NCT06404086	Phase 2	Completed	830	RECOVER-SLEEP platform: multi-intervention evaluation for sleep disturbances in Long COVID (PASC); specific interventions per appendix, modafinil role unclear from summary
NCT06404099	Phase 2	Active, not recruiting	361	RECOVER-SLEEP platform: ongoing evaluation of interventions for PASC sleep disturbances; results pending
NCT01965925	Phase 4	Completed	18	Modafinil for circadian and cognitive dysfunction in stable bipolar disorder; sleep measured as secondary endpoint — very small sample (n=18)
NCT00233090	Phase 2	Terminated	21	Modafinil vs. placebo for post-TBI fatigue; terminated early — insufficient evidence
NCT00626210	Phase 4	Terminated	2	Modafinil for sleep/wake disturbances in older adults; terminated after enrolling only 2 participants — no conclusions possible

Literature Evidence

PMID	Year	Type	Journal	Key Findings
18729534	2008	Evidence-based review	Drugs	Comprehensive RCT-based review of approved and investigational modafinil uses; confirms wake-promoting profile across narcolepsy, OSA, SWSD, and fatigue states — no support for primary insomnia treatment
24312590	2013	Systematic review / Meta-analysis	PLoS One	Modafinil significantly reduces fatigue and excessive daytime sleepiness in multiple neurological disorders; confirms unidirectional wake-promoting effect
27010071	2016	Cochrane-style systematic review	Parkinsonism & Related Disorders	Modafinil improves daytime sleepiness in Parkinson's disease; does not address insomnia as a treatment target
22021174	2011	EBM guideline review	Movement Disorders	MDS evidence-based review of non-motor Parkinson's treatments; modafinil recommended for excessive daytime sleepiness — not for insomnia
39535843	2024	Narrative review	Expert Opinion on Pharmacotherapy	Pharmacological and non-pharmacological management of sleep disturbances in Parkinson's disease; modafinil discussed for sleepiness, not insomnia
15824337	2005	RCT	Neurology	Modafinil for fatigue in multiple sclerosis; confirms wake-promoting effect — insomnia not an endpoint
18219235	2008	RCT	J Head Trauma Rehabilitation	Modafinil for fatigue and excessive daytime sleepiness in chronic TBI; no insomnia-specific endpoint
17181377	2006	Review	Drugs	Shift work sleep disorder: burden and management; modafinil reduces EDS in SWSD — directionality opposite to insomnia therapy
18805301	2008	Review	Revue Neurologique	Narcolepsy with cataplexy; sleep maintenance insomnia noted as a narcolepsy symptom, but modafinil's role targets daytime sleepiness, not nocturnal sleep
20166851	2010	Review	Expert Opinion on Emerging Drugs	Emerging treatments for narcolepsy; modafinil reviewed as the primary daytime EDS pharmacotherapy — not applicable to insomnia

Italy Market Information

Modafinil has no marketing authorizations currently registered in Italy. No license or approved indication data is available for this report.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This TxGNN prediction presents a fundamental mechanistic paradox — modafinil is a wake-promoting agent whose core pharmacology runs directly counter to the goal of insomnia therapy, and no completed RCT has demonstrated modafinil efficacy as a primary insomnia treatment. The high prediction score (99.85%) most likely reflects a knowledge-graph false positive arising from modafinil's broad presence in the sleep disorder disease space, not a genuine therapeutic signal.

To proceed, the following is needed:

A credible mechanistic hypothesis explaining how a wake-promoting agent could benefit insomnia (e.g., daytime wake consolidation improving nocturnal sleep architecture via homeostatic sleep pressure)
Retrieval of full EMA/AIFA package insert data (warnings, contraindications, drug interactions) before any further regulatory or clinical planning
Targeted mechanistic or preclinical study examining bidirectional sleep-wake effects of modafinil, particularly effects on nighttime sleep architecture (polysomnography)
If a plausible hypothesis emerges, a small Phase 2 proof-of-concept trial in primary insomnia with objective PSG-based endpoints would be required before any repurposing pathway can be considered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.